|Awarded On||May 20, 2015|
|Title||STOP HCC - Evidence-Based Hepatocellular Cancer Prevention Targeting Hepatitis C Virus Infection|
|Award Mechanism||Evidence-Based Prevention Programs and Services|
|Institution/Organization||The University of Texas Health Science Center at San Antonio|
|Principal Investigator/Program Director||Barbara J Turner|
|Cancer Sites||Gallbladder, Liver and Intrahepatic Bile Duct|
Hepatocellular carcinoma (HCC), the 9th leading cause of cancer-related death in the United States (U.S.), is one of the few cancers with an increasing incidence and mortality rate. Texas (TX) has the 2nd highest HCC incidence rate in the U.S. and is the fastest growing cancer in TX. Thus, there is a great need for evidence-based interventions to reduce HCC burden in the U.S., particularly TX.
Hepatitis C virus (HCV) is the dominant risk factor for HCC in the U.S. Citing strong evidence, in 2013 the U.S. Preventive Services Task Force endorsed screening all baby boomers (born 1945-65) for HCV infection and linking HCV-infected (HCV+) patients to treatment to prevent cirrhosis, HCC, and...